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Abstract: Anthocyanins are pigments with antihyperglycemic properties, and they are potential
candidates for developing functional foods for the therapy or prevention of Diabetes mellitus type 2
(DM2). The mechanism of these beneficial effects of anthocyanins are, however, hard to explain, given
their very low bioavailability due to poor intestinal absorption. We propose that free fatty acid receptor
1 (FFA1, also named GPR40), is involved in an inhibitory effect of the anthocyanidin delphinidin over
intestinal glucose absorption. We show the direct effects of delphinidin on the intestine using jejunum
samples from RF/J mice, and the human intestinal cell lines HT-29, Caco-2, and NCM460. By the use
of specific pharmacological antagonists, we determined that delphinidin inhibits glucose absorption in
both mouse jejunum and a human enterocytic cell line in a FFA1-dependent manner. Delphinidin also
affects the function of sodium-glucose cotransporter 1 (SGLT1). Intracellular signaling after FFA1
activation involved cAMP increase and cytosolic Ca2+ oscillations originated from intracellular Ca2+
stores and were followed by store-operated Ca2+ entry. Taken together, our results suggest a new
GPR-40 mediated local mechanism of action for delphinidin over intestinal cells that may in part
explain its antidiabetic effect. These findings are promising for the search for new prevention and
pharmacological treatment strategies for DM2 management.
Keywords: delphinidin; anthocyanins; SGLT1; glucose; GPR40; FFA1
1. Introduction
Intestinal glucose uptake control is a pharmacological target used for the control of
hyperglycaemia [1]. Metformin, an effective drug used as a first-line treatment in Diabetes mellitus
type 2 (DM2), is accumulated in the mucosa of the intestine increasing glucose turnover and
contributing to its antihyperglycaemic effect [2]. In isolated rat jejunal loops, metformin inhibited
the glucose-induced short-circuit current, thus reducing the activity of sodium-glucose transporter 1
(SGLT1), and simultaneously increasing the recruitment of glucose transporter 2 (GLUT2) to the apical
membrane of the rat jejunum [3]. Since metformin increases intestinal glucose uptake and also lactate
production [4,5], this phenomenon can cause intolerance to the treatment [5] and contribute to the
development of lactic acidosis [1].
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Diet is considered a useful non-pharmacological strategy for the control of glycaemia [1].
Recently, considerable attention has been focused on dietary constituents that may be beneficial
for the prevention and treatment of diabetes. Diet consumption of polyphenols such as anthocyanins
has been associated with a lower risk of DM2 [6–8].
Anthocyanins, which belong to the flavonoids group, are red or purple plant pigments, present in
the form of glycosides in berries. Beyond their anti-oxidant properties, it has been documented that
anthocyanins have anti-diabetic properties [9].
Dietary bilberry extract reduces the blood glucose level and enhances insulin sensitivity in type 2
diabetic mice, modulating GLUT4 in white adipose tissue and skeletal muscle, glucose output, and
lipid metabolism via AMP-activated protein kinase activation [9].
Anthocyanins such as cyanidin-3-glucoside and delphinidin-3-glucoside showed a high-level
capability to stimulate insulin secretion from rodent pancreaticβ cells in the presence of 4 and 10 mmol/L
glucose concentrations [10]. A formulation of anthocyanins or delphinidin 3-sambubioside-5-glucoside
decreased fasting blood glucose levels in obese C57BL/6J mice, while in vitro it decreased glucose
production in rat liver cells and increased glucose uptake in L6 myotubes [11]. Anthocyanins can
be directly absorbed from the gastrointestinal tract, however they show first-pass metabolism
(toward anthocyanidins, their aglycone form) by the gut microflora and hence have poor systemic
availability [12,13]. In fact, anthocyanins and the sugar-free form, anthocyanidins, are actively transported
out of intestinal tissues and endothelia, limiting their bioavailability in plasma [14]. These data suggest
that another unknown mechanism might be involved in the control of glycaemia by these pigments.
Recently, it has been described that delphinidin can directly induce the release of glucagon-like
peptide-1 from enteroendocrine L-cells, and therefore, it could stimulate glucose-dependent insulin
secretion in pancreatic β-cells via free fatty acid receptor 1 (FFA1) [15]. In spite of this, patients with
DM2 treated with a standardised bilberry extract (36% (w/w) anthocyanins) had reduced postprandial
glycaemia, but showed no significant increase of the GLP-1 level in plasma [16]. Delphidin increases
cytosolic free calcium, by releasing Ca2+ from intracellular stores and by increasing Ca2+ entry in
endothelial [17] and T cells [18]. It has been widely demonstrated that the intracellular calcium
concentration is involved in glucose transport [19]. However, by using L-type Ca2+ channel blockers,
an increase in the transport of hexose in rabbit jejunal tissue has been demonstrated, suggesting a more
complex role of calcium [20,21]. FFA1 agonist can activate calcium flux via the phospholipase C and
L-type Ca2+ channel [22], however, the direct effect of these drugs on glucose transport has not yet
been assessed. In this paper, we show evidence that delphinidin can reduce glucose uptake in the
intestine via stimulation of FFA1, by mechanisms other than incretin release.
2. Results
2.1. Delphinidin Inhibits Glucose Absorption in Mouse Jejunal
In order to initially evaluate a possible inhibitory effect of delphinidine on intestinal glucose
transport, we decided to study its effect on the electrogenic sodium-coupled glucose transport.
Experiments with mouse intestinal preparations in the Ussing chamber (Figure 1A,B) showed
that treatment of the jejunal mucosa with 100 µM delphinidin is able to reduce the short-circuit
current induced by the addition of 10 mM glucose to the mucosal side. The differences were
statistically significant.
Since the electrophysiological study carried out only allows for the evaluation of the function of the
SGLT1 co-transporter, we decided to complement it by performing uptake assays with a radiolabeled
glucose analogue in everted sacs of mouse jejunum sections. The results showed that treatment with
100 µM delphinidin significantly inhibited the incorporation of 3-O-methyl-glucose [3H] (3-OMG) in
the mouse intestine (Figure 1C), an effect that is similar to that of phlorizin 1 mM, a pharmacological
inhibitor of the electrogenic transport of glucose, which was used as a positive control.
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Figure 1. Delphinidin inhibits intestinal glucose absorption. (A) Sample tracing showing changes in 
short-circuit current during an experiment using 10 mM glucose and 100 μm delphinidin; (B) 
Summary of Ussing experiments in Rockefeller mice (RF/J); (C) Effect of DMSO 0.2% (control), 
delphinidin 100 μM, or phlorizin on 3-O-methyl-glucose-3H absorption. A glucose uptake is shown 
as counts per minute per gram of tissue (CPM/g). Bars represent mean ± SEM of at least six different 
animals. * p < 0.05 compared to glucose; ** p < 0.01 *** p < 0.001 compared to the control. 
In order to determine whether this inhibition of glucose uptake was mediated by the activation 
of FFA1, we repeated the experiment but added a pre-incubation step of 15 min with pharmacological 
antagonists of this receptor or vehicle (Figure 2A,B). In these trials, 100 μM delphinidin and the 
synthetic FFA1 agonist, TAK 875, inhibited the incorporation of glucose significantly (Figure 2A). 
Tissues pretreated with any of the FFA1 receptor antagonists, DC260126 (Figure 2A), or GW1100 
(Figure 2B), interfered with the inhibition of the intestinal glucose uptake produced by delphinidin. 
In order to study the molecular mechanisms of signaling related to the inhibitory effect of delphinidin 
Glucose
0 2 4 6
-14
-12
-10
-8
Time (min)
Is
c 
( μ
A 
cm
-2
) Delphinidin
A
Gl
uc
os
e 1
0m
M Mμ
Gl
uc
. +
 D
elp
hin
idi
n 1
00
-5
-4
-3
-2
-1
0
ΔI
sc
 ( μ
A 
cm
-2
)
B
Co
ntr
ol Mμ
De
lph
ini
din
 10
0
Ph
lor
izi
n 1
mM
0
2000
4000
6000
8000
***
**
3-
O
M
G
 u
pt
ak
e
(C
PM
/g
)
C
*
Figure 1. Delphinidin inhibits intestinal glucose absorption. (A) Sample tracing showing changes in
short-circuit current during an experiment using 10 mM glucose and 100 µm delphinidin; (B) Summary
of Ussing experiments in Rockefeller mice (RF/J); (C) Effect of DMSO 0.2% (control), delphinidin 100
µM, or phlorizin on 3-O-methyl-glucose-3H absorption. A glucose uptake is shown as counts per
minute per gram of tissue (CPM/g). Bars represent mean ± SEM of at least six different animals.
* p < 0.05 compared to glucose; ** p < 0.01 *** p < 0.001 compared to the control.
In order to determine whether this inhibition of glucose uptake was mediated by the activation of
FFA1, we repeated the experiment but added a pre-incubation step of 15 in with pharmacological
antagonists of this receptor or vehicle (Figure 2A,B). In these trials, 100 µM delphinidin and the
synthetic FFA1 agonist, TAK 875, inhibited the incorporation of glucose significantly (Figure 2A).
Tissues pretreated with any of the FFA1 receptor antagonists, DC260126 (Figure 2A), or GW1100
(Figure 2B), interfered with the inhibition of the intestinal glucose uptake produced by delphinidin.
In order to study the molecular mechanisms of signaling related to the inhibitory effect of delphinidin
on the uptake of glucose in the intestine, we decided to interfere with the activation of the PI3K/Akt
kinase pathway through the pharmacological inhibitor of PI3K, LY294002 (Figure 2C), and to
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interfere with the mobilization of intracellular calcium by the use of the intracellular calcium chelator
BAPTA-AM (Figure 2D). In tissues pretreated with 50 µM BAPTA-AM, delphinidin showed no
significant inhibition on glucose uptake, whereas in tissues pretreated with the vehicle (0.2% DMSO)
or 10 µM LY294002, delphinidin still showed a significant inhibitory effect on glucose uptake.
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Figure 2. Inhibition of intestinal glucose uptake produced by delphinidin depends on FFA1 and
intracellular calcium. Uptake of 3-O-methyl-glucose [3H] is expressed in counts per minute per gram
of tissue (CPM/g). The effects of FFA1 antagonist DC260126 (A) and GW1100 (B) on delphinidin are
depicted. The effect of FFA1 agonist TAK875 on 3-OMG uptake, is shown (A). The effect of LY294002,
a PI3K Inhibitor, (C) or BAPTA-AM (D) are shown. Additionally Phlorizin, a SGT1 inhibitor, was used.
The bars represent the mean ± standard error of the mean of at least six animals. * p < 0.05, ** p < 0.01,
*** p < 0.001, compared with the control. Delph. = 100 µM delphinidin.
2.2. Presence of FFA1 in Caco-2 and HT-29
Having observed the inhibitory effect of delphinidin on the intestinal absorption of glucose,
and its dependence of calcium and the activation of FFA1, we decided to study in more detail the
signaling involved using a cellular model. The presence of the FFA1 receptor was detected in the
Int. J. Mol. Sci. 2017, 18, 750 5 of 18
HT-29 enterocyte-like human cell line by Western blot (Figure 3A) and by immunofluorescence using
a confocal microscope (Figure 3B), and was confirmed by immunofluorescence measured by flow
cytometry (Figure 3C) and qRT-PCR (Figure 3D).
Int. J. Mol. Sci. 2017, 18, 750  5 of 17 
 
2.2. Presence of FFA1 in Caco-2 and HT-29 
Having observed the inhibitory effect of delphinidin on the intestinal absorption of glucose, and 
its dependence of calcium and the activation of FFA1, we decided to study in more detail the 
signaling involved using a cellular model. The presence of the FFA1 receptor was detected in the HT-
29 enterocyte-like human cell line by Western blot (Figure 3A) and by immunofluorescence using a 
confocal microscope (Figure 3B), and was confirmed by im unofluorescence measured by flow 
cytometry (Figure 3C) and qRT-PCR (Figure 3D). 
 
Figure 3. HT-29 and Caco-2 cells express FFA1. (A) Immunoblot of FFA1 in HT-29 and Caco-2 cells. 
A single band near 28 kDa was observed in at least three different assays. The β-actin loading control 
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Figure 3. HT-29 and Caco-2 cells express FFA1. (A) Immunoblot of FFA1 in HT-29 and Caco-2 cells.
A single band near 28 kDa was observed in at least three different assays. The β-actin loading control
is shown. Immunofluorescence microscopy of FFA1 in HT-29 Cells and Caco-2 Cells. (B) Monoclonal
anti-FFA1 antibody was used as the primary antibody, with an Alexa-488-bound fluorescent secondary
antibody. Nuclei were stained using Hoechst 33342. Scale bar corresponds to 10 µm; (C) Flow cytometry
of FFA1 in HT-29 cells. Monoclonal anti-FFA1 rabbit antibody and secondary Alexa-488 bound
antibody were used. Results are shown as counts in the Y axis, and fluorescence intensity in the
X axis. (Representative experiment from two were carried out); (D) qRT-PCR of FFA1 in HT-29 cells.
The amplicon for FFA1 is shown in red.
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2.3. Delphinidin Induces Intracellular Calcium Release in HT-29 Cells via FFA1
Using the HT-29 enterocytic line, intracellular calcium measurements in cell populations were
carried out with the FURA-2AM fluorescent probe (Figure 4). It was observed that delphinidin was able
to induce an increase in intracellular calcium concentrations in a dose-dependent manner (Figure 4B).
Upon pre-incubation with the FFA1 antagonist GW1100 (10 µM) for 15 min, the intracellular calcium
signal induced by 50 µM delphinidin was diminished (Figure 4C,D)
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2.4. elphi i i I il tio s in T-29 Cel s in a Ca2+ t re- ependent Manner
In order to examine the intracellular calcium signals induced by delphinidin in more detail,
we decided to perform measu ements at the single cell level (Figure 5). At this resolution, it was
observed that the intr cellular calcium gnals produced by delphinidin were actually in the form
of oscillations (Figure 5A), that usually started within a few minutes of trea ment and which were
recorded at concentr tions of elphinidin that were even 20 times lower than those ffective t
inhibiting the transport of glucose analogues in the jejunum from mice (Figure 5C). On the other hand,
50 µM Delphinidin-3,5-glucoside did not induce the effect observed with delphinidin.
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Figure 5. Delphinidin induces intracellular calcium oscillations in HT-29 cells. (A) Delphinidin-induced
intracellular calcium oscillations at the single-cell level. Each colored line represents calcium recordings
of individual cells in the same microscopic field. The horizontal bar depicts the duration of
delphinidin perfusion; (B) Representative tracing of the mean calcium (± SEM) response of 16 cells
treated for 6 min with either Delphinidin-3,5-glucoside 50 µM (red) or Delphinidin 50 µM (black);
(C) Area-under-the-curve (AUC) data from dose-response experiments on HT-29 cells. Bars represent
mean ± SEM of 16–20 cells. *** p < 0.001.
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re ro ce i an extracell lar calci -free e i ( i re 6 ), res lti i a s aller average
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fter t e obser ati t at calci oscillati s ca e ge erate i the absence of extracell lar
calciu , e eci e t c fir if i tracell lar st res are i l e i i tracell lar calci scillati s
by using 30 µM cyclopiazonic acid, a specific inhibitor of the sarcoplasmic and endoplasmic reticulum
Ca2+-ATPase (SERCA) of intracellular deposits, that depletes Ca2+ stores passively. In this condition,
the stimulation with delphinidin was ot able to generate the oscillations of intracellular calci m
(Figure 6C,D).
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2.5. Delphinidin Induces Intracellular Calcium Oscilations via FFA1 in Colon Normal Cells
Although HT-29 cells are used as a model for human enterocytes, they may behave differently
from normal uman intestinal mucosa cells [23] as t ey re derived from adenocarcinoma. With this
in i d, we decided to test the same experiment using normal human colon mucosa cells NCM460.
I tracellular calcium scillations, induced by delphinidin but not Delphi idin-3,5-glucoside, also
occurr d in these cells, this time at minimum conc ntrations up o 200 times lower than those that had
an effect o the uptake of glucos nalogues in the mouse jejunum (Figure 7A,B). Delphinidin-induced
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calcium oscillations could also be seen in calcium-free extracellular conditions, and adding calcium
before the end of measurements once again prompted a fast calcium influx (Figure 7C,D).
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in NCM460 Fura-2 AM loaded cells. (A) Representative recording (mean ± SEM) corresponding
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To determine if intracellular store-dependent calcium oscillations produced by delphinidin were
secondary to the activation of FFA1, calcium measurements were performed on cells exposed to 5 µM
delphinidin after being pretreated with the FFA1 antagonist, GW1100 (Figure 8). A significantly lower
response to delphinidin was noted in NCM460 cells pretreated with 10 µM GW1100 versus the vehicle
(Figure 8B).
2.6. Delphinidin Induces Intracellular Calcium Release, cAMP, and Glucose Uptake via FFA1
To assess whether the effects of delphinidin observed on glucose transport in mouse jejunum
would also be replicated in a human enterocytic cell line, assays were performed for the uptake of
radiolabeled glucose analogs into Caco-2 cells. These cells were selected for glucose uptake assays due
to their tendency to spontaneously differentiate into a polarized monolayer of mature enterocytes [23],
emulating an epithelial barrier. In cells stimulated with delphinidin at a concentration of 50 µM
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for 15 min, glucose uptake was significantly reduced compared to the vehicle, except in those cells
pretreated with the FFA1 antagonist, GW1100, at 10 µM concentration (Figure 9A).
Finally, in order to further characterize the intracellular signaling induced by delphinidin, we
evaluated its effect on the concentration of intracellular cyclic AMP in Caco-2 cells. The luminometric
assay demonstrated that incubation with 50 µM delphinidin for 15 min induces a significant increase in
cyclic AMP concentration compared to vehicle treatment (Figure 9D). This response was not observed
in cells pre-incubated with GW1100.
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Figure 8. Calcium increase induced by delphinidin in NCM460 Fura-2 AM loaded cells are inhibited
by FFA1 antagonist GW1100. (A) Temporal course of the ratio F340/380 of HT-29 cells pre-incubated
for 15 min with 10 µM GW1100 or vehicle (0.1% DMSO) and then stimulated with 5 µM delphinidin;
(B) The bar graph indicates the mean area under the curve ± SEM of four experiments. * p < 0.05.
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Figure 9. Delphinidin induced inhibition of glucose uptake, intracellular Ca2+, and cAMP increase
in Caco-2 cell monolayers is reversed by FFA1 antagonist. (A) Effect of GW1100 on glucose uptake
induced by delphinidin. Each bar represent the mean ± SEM of seven different experiments; (B) Effect
of delphinidin on Caco-2 Fura-2 AM loaded cells or in the presence of GW1100 (C); (D) cAMP
measurements, bars represent mean ± SEM of four independent experiments. * p < 0.05, *** p < 0.001.
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3. Discussion
Polyphenols are known to interact directly with glucose transporters to regulate the rate of glucose
absorption [24], reducing electrogenic glucose uptake [25]. Our results suggest that delphinidin reduces
electrogenic glucose uptake because its addition decreases the glucose-induced short-circuit current in
the jejunum of mice. In the present study, we show new evidence suggesting that delphinidin could
directly inhibit the total uptake of glucose in the gut via the FFA1 receptor. This effect of FFA1 on
glucose uptake has not been described before, however the roles of FFA1 in glycaemia homeostasis are
widely known. The activation of the FFA1 receptor, expressed in L cells and the pancreas, is useful in
the control of diabetes via insulin release [26,27]. Also, it has been recently described in the murine
GLUTag L cell line that delphinidin can increase GLP-1 secretion via FFA1 [15], which could explain
the reduction of glycaemia observed with the administration of anthocyanins in DM2. TAK875 and
natural FFA1 agonists such as long-chain free fatty acids, directly stimulate insulin release by the
pancreas and incretin release by enteroendocrine cells when arriving at the cell from the vascular
side, but not the luminal side [28,29]; these effects require an absorption process prior to stimulating
GLP-1 secretion [30]. This is unlikely with delphinidin, because several reports establish that the
bioavailability of anthocyanidins is scarce [12,13]. In support of a direct effect of delphinidin on
glucose absorption in the gut, we observed that delphidinin reduced the uptake of 3-OMG in mouse
everted jejunal ring, and GW1100 and CD260126, two antagonists of FFA1, interfered with the effect
of delphinidin. FFA1 activation results in the coupling to the Gαq/11 subunit, enhancing PLC, IP3,
and DAG, which stimulates intracellular Ca2+ from the endoplasmic reticulum [26,27]. In HT-29 cells,
delphinidin induces intracellular Ca2+ release characterized by calcium oscillations. The calcium
oscillations are initiated when the equilibrium in the basal cytosolic Ca2+ level is perturbed. This can
occur when the cell senses extracellular stimuli that result in the activation of calcium channels or
pumps such as sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), that regulate the intracellular
Ca2+ concentration [31]. Using Ca2+ free medium and cyclopiazonic acid, a reversible SERCA blocker,
we demonstrated that delphinidin induces intracellular calcium oscillations via store-operated calcium
entry SOCE in HT-29. Similarly, other authors have shown that intracellular calcium oscillations are
abolished by depleting intracellular calcium stores with cyclopiazonic acid [32]. The SOCE in HT-29
cells has been described before [33], being mediated by the calcium channels ORAI1 and TRPC1 [34].
Agonist-induced Ca2+ increases, SOCE, and store-operated currents (ISOC) are largely enhanced in
tumor cells, like HT-29 [34], and could limit the interpretation of our results. However, using NCM460
cells (normal human colon mucosa cells), similar intracellular calcium oscillations were observed
with delphinidin. Moreover, delphinidin-induced intracellular calcium oscillations have also been
described in bovine aortic endothelial cells, and this response was also inhibited by using thapsigargin,
a SERCA blocker [17].
We observed that delphinidin-3,5-di-glucoside did not induce intracellular calcium oscillations in
HT-29 and NCM460, suggesting that anthocyanins, e.g., glycosides of delphinidin, could be a poor
FFA1 agonist. In support of this, other authors had previously described that glucosyl anthocyanins
did not activate the FFA1 receptors [15].
In order to assess the effect of delphinidin on glucose uptake in intestinal cells, we used
differentiated Caco-2 cells. Again, delphinidin was able to release intracellular Ca+2 and reduce the
uptake of 3-OMG via FFA1. Other authors have demonstrated the inhibition of 3H-D-glucose uptake
in Caco-2 cells using anthocyanin-rich berry extract [35]. Eicosapentaenoic acid (EPA), a natural FFA1
agonist [26,36], also releases Ca2+ from the endoplasmic reticulum in colonic epithelial cells, followed
by the “store operated” cAMP increase [37]. In a similar way, we demonstrated that delphinidin
increases cAMP production in Caco-2 cells via FFA1. There is recent evidence that certain FFA1 ligands
can cause the receptor to couple selectively to the Gq or Gs protein [38], with those agonists that can
simultaneously activate both pathways being more effective [39]. Previously, this has been described
in enteroendocrine cells; however, absorptive intestinal cells and enteroendocrine cells share many
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common signaling elements, including GPCRs, SGLT1, Ca2+, and cAMP [40], and thus could show
similar responses upon FFA1 activation.
In spite of these findings, we cannot exclude the possibility that delphinidin may also affect other
FFA receptors, since delphinidin could exert dual agonist effects on FFA1/FFA4 in intestinal cells [15].
Moreover, another FFA1 natural agonist, e.g., EPA, can also release Ca2+ via FFA4 in human colon
epithelial cell lines [41].
Altogether, our results suggest that delphinidin can reduce the uptake of glucose in intestinal
cells via FFA1, and could explain the reduction of postprandial blood glucose observed with
anthocyanins [7,16,42–45]. Moreover, it would represent a new natural ligand class, beyond the
well-known activity of long chain fatty acids.
4. Materials and Methods
4.1. Ussing Chamber Experiments
All animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee of the Centro de Estudios Científicos (121DL2-16254, 10-03-2014), according to national
regulations. The animal facility of the Centro de Estudios Científicos is accredited by The Association
for Assessment and Accreditation of Laboratory Animal Care (Frederick, MD, USA). All animals were
fed with 10% kcal% fat (3.85 kcal/g) from Research Diets Inc. (New Brunswick, NJ, USA) which was
composed of carbohydrate 67.3%, protein 19.2%, fat 4.3%, and minerals and vitamins 2.1%. Animals of
22 ± 2 g of body weigth, were killed by cervical dislocation and jejunum was isolated and opened
longitudinally along the mesenteric border and then rinsed with phosphate buffered saline (PBS).
Mouse small intestine samples were selected from jejunal tissue, because duodenal or jejunum show
an equivalent pattern of glucose absorption in mice with similar Vmax and Km [46]. Two sections of
jejunum per animal were mounted in Ussing Chambers and maintained in Ussing buffer (120 mM
NaCl, 25 mM NaHCO3, KH2PO4 3.3 mM, 0.8 mM K2HPO4, 1.2 mM MgCl2, and 1.2 mM CaCl2)
supplemented with 10 mM D-glucose in the serosal side. The temperature was maintained at 37 ◦C
and the solution was continuously gassed with carbogen containing 5% CO2. Once the preparation
reached a stable record of electrical parameters, 10 mM D-glucose was added to the mucosal side of the
preparation in order to stimulate the Na+ coupled D-glucose transport. The effect of 100 µM delphinidin
on Na+-coupled transport of glucose was determined by its application to the mucosal side of the
preparation. The transepithelial electrical potential difference (Vte) was recorded continuously under
the current clamp configuration using a VCC MC2 amplifier (Physiological Instruments). The values of
the short circuit current (Isc) were calculated from the experimental data using Ohm’s law. Results were
expressed as intensity of Isc or the difference (∆Isc) before—after the addition of 10 mM glucose and
before—after the addition of 100 µM delphinidin, as described previously [47].
4.2. Flow Cytometry Analysis of FFA1 Expression
HT-29 cells cultured in 35 mm dishes were lifted by trypsinization at 37 ◦C, trypsin activity was
stopped by the addition of a complete culture medium, and then cells were pelleted by centrifugation
at 600× g for 5 min, and afterwards were fixed by 4% paraformaldehyde for 10 min at 37 ◦C. Then, they
were cooled in ice for 1 min, before being centrifuged at 600× g for 5 min and resuspended using
90% methanol in PBS (137 mM NaCl; 2.7 mM KCl; 10 mM NaHPO4; 2 mM KH2PO4). Cells were
then incubated for 30 min at 4 ◦C, washed twice with PBS, and treated for 60 min with monoclonal
anti-FFA1 antibody (rabbit, Abcam, Cambridge, MA, USA) or Isotype control IgG (rabbit, Abcam) at
4 ◦C. Afterwards, cells were washed twice with PBS and marked with the anti-rabbit Alexa488-bound
secondary antibody for 60 min in darkness. Finally, the cells were washed and then resuspended in PBS.
Using a FACSCanto II cytometer (BD Biosciences, San Diego, CA, USA), the cells were displayed as
plots of forward light scatter versus side light scatter, and the cell population was identified. The mean
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fluorescence of Alexa488 was determined from a minimum of 10,000 cells using BD FACSDiva 6.1
software (BD Biosciences).
4.3. Glucose Uptake Experiments—Tissue
Methyl-D-Glucose, 3-O-[Methyl-3H(N)] (lot:657433 Perkin Elmer, Santiago, Chile) uptake was
measured in everted jejunal rings [48]. Jejunum from mice was everted and then washed in cold
Ringer’s solution (115 mM NaCl, 25 mM NaHCO3, 1.2 mM MgCl2, 1.2 mM CaCl2, 2.4 mM K2HPO4,
0.4 mM KH2PO4, pH 7.3) previously bubbled with carbogen (95% O2, 5% CO2). The sample was then
cut into four rings of 0.5 cm length each, which were weighed and then pre-incubated for 15 min in
Ringer’s solution constantly bubbled with carbogen at 37 ◦C with the addition of one of the following:
vehicle (0.1% DMSO), a FFA1 antagonist (either 10 µM GW1100 or 10 µM DC260126), or a calcium
chelator (50 µM BAPTA). Afterwards, the rings were treated for 15 min with one of the following: 0.2%
DMSO (vehicle), 1 mM phlorizin, 100 µM delphinidin, or 10 µM TAK875, before incubation for 2 min
in uptake solution (Ringer’s solution bubbled with carbogen plus 10 mM glucose and 0.1 µCi/mL
of the isotopic tracer 3-O-methyl glucose). Then, the rings were washed with cold Ringer’s solution
containing 100 µM cytochalasin B. Tissues were digested in 10% v/v nitric acid for 24 h and the
radioactivity of the supernatant was measured in a Tri-carb 2810 TR liquid scintillation counter.
4.4. Glucose Uptake Experiments—Cultured Cells
Methyl-D-Glucose, 3-O-[Methyl-3H(N)] (lot:657433 Perkin Elmer, Santiago, Chile) uptake was
measured in Caco-2 cell monolayers. The Caco-2 cell line is derived from a human colon adenocarcinoma
and grows as a monolayer of differentiated polarized cells, showing structural and functional features
of small intestinal enterocytes [49,50]. Cultured cells were seeded in 12-well culture plates, at a density
of 4 × 105 cells per well. After 24 to 48 h, the culture medium was eliminated and replaced by
a differentiation medium (DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 2 mM
sodium butyrate, pH 7.4; modified from Yamashita et al. [51]). After 5 days, the cells were carefully
washed and then incubated for 5 min in Ringer’s solution without glucose. Afterwards, the cells
were incubated for 15 min in either 0.1% DMSO (vehicle) or 10 µM GW1100, before being treated for
15 min with 50 µM delphinidin or 0.1% DMSO as a negative control. Cells were then incubated for
15 min in cell uptake solution (Ringer’s solution plus 1 mM glucose and 0.3 µCi/mL of the isotopic
tracer 3-O-methyl glucose). After uptake, cells were exhaustively washed with cold Ringer’s solution
plus 10 µM cytochalasin B, then lysed in 1 M NaOH for 24 h. Radioactivity of the supernatant was
measured in a Tri-carb 2810 TR liquid scintillation counter.
4.5. Western Blot
Cultured Caco-2 and HT-29 cells were lysed in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl,
5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 mg/mL PMSF) with the addition
of the “complete®” commercial protease inhibitor cocktail (Roche) at 4 ◦C. Protein concentration was
determined using the Bradford assay. 50 µg of total proteins were resolved by SDS–PAGE on a 12%
polyacrylamide/0.1% SDS gel and were transferred onto a nitrocellulose membrane. After blocking
with 5% non-fat dry milk, the membranes were incubated overnight at 4 ◦C with Anti-FFA1 antibody
(rabbit, Abcam) using a 1:1000 dilution. The membrane was washed three times in Tris-buffered saline
and was then exposed to 1:5000 anti-rabbit-IgG antibody conjugated with horseradish peroxidase
(Cell Signaling, Danvers, MA, USA) for 1 h at room temperature. Blocked antibody solutions were
prepared with 1% fat-free milk phosphate-buffered saline (PBS)–Tween 0.1% (PBST), and signals were
detected with an enhanced chemiluminescence system. For loading control of FFA1, the antibody
was removed by incubation with stripping solution (100 mM 2-mercaptoethanol; 2% SDS; 62.5 mM
Tris-HCl, pH 6.7) for 0.5 h at 50 ◦C with agitation, followed by several washes with TBS-Tween 0.1%.
The membrane was then incubated with anti-β-actin antibody (Sigma-Aldrich Quimica Limitada,
Santiago, Chile, #A5441) at a dilution of 1:6000, using a procedure similar to that described above.
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4.6. Immunofluorescence
Cells were grown on coverslips coated with poly-L-lysine, fixed with 4% paraformaldehyde and
permeabilized using 0.3% Triton X-100 for 10 min. Afterwards, they were washed with PBS (137 mM
NaCl; 2.7 mM KCl; 10 mM NaHPO4; 2 mM KH2PO4), and were then incubated for 1 h in blocking
solution (1% Bovine serum albumin plus 5% non-fat milk in PBS) at room temperature, before being
incubated overnight with monoclonal anti-FFA1 antibody (rabbit, Abcam) at 4 ◦C. On the next day,
the cells were washed in PBS and then incubated for 2 h with secondary antibody (Alexa488-bound
anti-rabbit antibody). Hoescht 33342 (Invitrogen, Waltham, MA, USA ) was used to stain the cell nuclei.
Samples were treated with DAKO Fluorescent mounting medium (Sigma) and then visualized using
an inverted Olympus FluoView 1000 confocal microscope (GrupoBios S.A, Santiago, Chile).
4.7. Cytosolic Ca2+ Monitoring in Cell Suspensions
Fura-2 AM-loaded HT-29 and Caco-2 cells were suspended in HEPES/Ca2+ extracellular medium
(145 mM NaCl, 5 mM KC l, 1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, 10 mM glucose, pH 7.42).
Cells were pre-treated for 15 min with either 0.1% DMSO or 10 µM GW100, then stimulated with
delphinidin at a concentration of 25, 50, or 100 µM. Fluorescence emission at 509 nm wavelength was
recorded after alternate excitation at 340:380 nm using a LS55 thermoregulated spectrofluorimeter
(Perkin-Elmer, Waltham, MA, USA ).
4.8. qRT-PCR of FFA1 in HT-29 Cells
Total RNA extraction was done with the commercial kit E.Z.N.A. Total RNA Kit I (Omega Bio-Tek,
Atlanta, GA, USA). Then the cDNA was made from 1 µg of total RNA with reverse transcriptase
M-MLV (Promega, Madison, WI, USA). Finally, a conventional PCR of 40 cycles (denaturation 30 s at
95 ◦C, alignment 30 s at 55 ◦C, and elongation 1 min at 72 ◦C) was performed with a GoTaq Green
Master Mix (Promega). The primers were designed against FFA1 sense: CTGGTCTACGCCCTGAACCT;
antisense: GAGCCTCCAACCCAAAGACC.
4.9. Cytosolic Ca2+ Imaging in Adhered Cells
Intracellular calcium was measured by fluorescence microscopy as described by Núñez et al. [52].
Cultured cells were seeded on 12 mm cover glasses. After 24 h, cells were loaded with 4 µM Fura-2
AM for 60 min in a HEPES/Ca2+ extracellular medium (145 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1 mM CaCl2, 10 mM HEPES, 10 mM glucose, pH 7.42). For experiments with the FFA1 antagonist, the
final 30 min of loading also included pre-incubation with 10 µM GW1100. Afterwards, the cells were
placed on a platform attached to the stage of an inverted Zeiss Axiovert microscope equipped with
an OrcaER Hamamatsu digital camera, where they were constantly perfused with HEPES/Ca2+ at
37 ◦C. For calcium-free extracellular medium experiments, the perfusion was then switched to HEPES
calcium-free extracellular medium (145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM HEPES, 10 M
glucose, 0.5 mM EGTA). Cells were epi-illuminated alternately at 340 and 380 nm wavelengths, and
the light emitted above 520 nm was recorded every 5 s.
4.10. cAMP Measurements
Caco-2 cells were seeded at a density of 4000 cells per well in flat clear-bottom poly-D-Lysine
treated 384-well microplates (Corning, New York, NY, USA). On the next day, cells were treated with
10 µM GW1100 (FFA1 antagonist) or 0.1% DMSO (vehicle) for 15 min, and were then treated with
delphinidin 50 µM, DMSO 0.1%, or Forskolin 5 µM (as positive control) for 15 min. Cytosolic cAMP
concentrations were determined using the commercial “cAMP-Glo®A” luciferase-based assay kit
(Promega), following the manufacturer’s instructions, including treatment with phosphodiesterase
inhibitors (100 µM RO 20-1724 and 100 µM IBMX in DMEM culture medium without FCS). Finally, the
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luminiscence was measured in a Luminoskan Ascent microplate luminometer (Thermo Scientific,
Waltham, MA, USA).
4.11. Statistical Analysis
Normality was checked by the Kolmogorov-Smirnov test. For comparisons between two groups,
the Student’s t test was used. For more than two groups, analysis of variance was performed, followed
by the Newman-Keuls multiple comparisons test. For correlated experimental data, randomized block
ANOVA was used, as suggested by Lew [53].
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